| Clinical data | |
|---|---|
| Other names | PX-866 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.243.047 |
| Chemical and physical data | |
| Formula | C29H35NO8 |
| Molar mass | 525.598 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sonolisib (PX-866) is a experimental drug that has been shown to be an irreversible inhibitor of PI-3 kinase with efficacy when delivered orally. It is an analog of the natural chemical compound wortmannin.
Sonolisib was put in a phase 1 clinical trial by Oncothyreon. The clinical development plan for sonolisib includes both standalone and combination therapy in major human cancers. In 2010, sonolisib was starting 4 phase II trials for solid tumors. The company gave an update on its phase 2 trials in Jun 2012. Phase 1 results (with docetaxel) published Aug 2013. In July 2014 published results of a phase 2 trial (for NSCLC) concluded : "The addition of PX-866 to docetaxel did not improve PFS, response rate, or OS in patients with advanced, refractory NSCLC without molecular preselection". In Sept 2015 as Phase 2 trial for recurrent glioblastoma reported not meeting its primary endpoint.